Skip to content

A promising pipeline

Take a closer look at the progress of our first-in-class therapeutics.

Drug Indication* Phase I Phase II Phase III FDA Approved Commercialization Rights
(ex-Japan and S. Korea)
Difelikefalin injection Pruritus CKD-HD§ Commercial Rights: US-Vifor
EU / Other-VFMCRP||
US-Vifor
EU / Other-VFMCRP||
Oral difelikefalin Pruritus AD Commercial Rights: Cara
Cara
Oral difelikefalin Pruritus NDD-CKD Commercial Rights: Cara
Cara
Oral difelikefalin Pruritus PBC Commercial Rights: Cara
Cara
Oral difelikefalin Pruritus NP Commercial Rights: Cara
Cara
  1. *Cara Therapeutics has investigated difelikefalin for post-operative pain.
  2. Vifor has commercial rights in Non-US Fresenius Medical Care dialysis clinics under a profit-share arrangement.
  3. Commercialization rights to difelikefalin in defined indications—Japan: Maruishi Pharma; South Korea: CKD Pharma.
  4. §Approved for USA.
  5. ||VFMCRP and Cara have rights to promote in Fresenius clinics in the US under a profit-share agreement.
  6. CKD-HD: Chronic Kidney Disease-Hemodialysis; NDD—CKD: Non-Dialysis Dependent-Chronic Kidney Disease; AD: Atopic Dermatitis; PBC: Primary Biliary Cholangitis; NP: Notalgia Paresthetica.